A Phase 2b Evaluation of Daclatasvir/Sofosbuvir in Non-Cirrhotic Treatment Naive Subjects With Genotype 1, 2, 3 and 4 Chronic Hepatitis C Virus Coinfected With Human Immunodeficiency Virus (HIV-1)
A Phase 2b Evaluation of Daclatasvir/Sofosbuvir in Non-Cirrhotic Treatment Naive Subjects With Genotype 1, 2, 3 and 4 Chronic Hepatitis C Virus Coinfected With Human Immunodeficiency Virus (HIV-1)
The purpose of the study is to determine if combination therapy with daclatasvir (DCV) and
 sofosbuvir (SOF) for 8 weeks is safe and effective in patients who have never been treated
 previously without liver cirrhosis who are chronically infected with hepatitis C virus
 (HCV)/HIV-1 Coinfection genotype (GT) 1, 2, 3, 4 patients.
For more information regarding BMS clinical trial participation, please visit
 www.BMSStudyConnect.com

 Inclusion Criteria:

 -  HCV RNA < 2000000 IU/mL

 -  Never taken medication for HCV

 -  No Liver Cirrhosis

 -  No advanced fibrosis

 -  Body mass index(BMI) 18-40 kg/m^2

 -  Genotype 1-4

 Exclusion Criteria:

 -  Infection with HCV other than GT-1, 2, 3 or GT-4 or subjects with mixed infections of
 any genotype

 -  Evidence of decompensated liver

 -  Subjects Infected with HIV 2

 -  Hepatitis B virus (HBV) coinfection

 -  Liver Cirrhosis

 -  Advanced fibrosis (F3-F4)